Cargando…
Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051796/ https://www.ncbi.nlm.nih.gov/pubmed/24940041 http://dx.doi.org/10.2147/OPTH.S40798 |
_version_ | 1782320151390060544 |
---|---|
author | Kashima, Tomoyuki Itakura, Hirotaka Akiyama, Hideo Kishi, Shoji |
author_facet | Kashima, Tomoyuki Itakura, Hirotaka Akiyama, Hideo Kishi, Shoji |
author_sort | Kashima, Tomoyuki |
collection | PubMed |
description | Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury. Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability. Topical rebamipide has also been shown to be effective in treating other ocular surface disorders such as lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion. Rebamipide’s ability to modify epithelial cell function, improve tear stability, and suppress inflammation in the absence of any known major side effects suggest that it may be a beneficial first drug of choice for severe dry eye treatment and other ocular surface disorders. This review summarizes the history and development of this innovative dry eye treatment from its initial use as an effective stomach medication to its current use in the treatment of dry eye in Japan. |
format | Online Article Text |
id | pubmed-4051796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40517962014-06-17 Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal Kashima, Tomoyuki Itakura, Hirotaka Akiyama, Hideo Kishi, Shoji Clin Ophthalmol Review Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury. Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability. Topical rebamipide has also been shown to be effective in treating other ocular surface disorders such as lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion. Rebamipide’s ability to modify epithelial cell function, improve tear stability, and suppress inflammation in the absence of any known major side effects suggest that it may be a beneficial first drug of choice for severe dry eye treatment and other ocular surface disorders. This review summarizes the history and development of this innovative dry eye treatment from its initial use as an effective stomach medication to its current use in the treatment of dry eye in Japan. Dove Medical Press 2014-05-30 /pmc/articles/PMC4051796/ /pubmed/24940041 http://dx.doi.org/10.2147/OPTH.S40798 Text en © 2014 Kashima et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Kashima, Tomoyuki Itakura, Hirotaka Akiyama, Hideo Kishi, Shoji Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
title | Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
title_full | Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
title_fullStr | Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
title_full_unstemmed | Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
title_short | Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
title_sort | rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051796/ https://www.ncbi.nlm.nih.gov/pubmed/24940041 http://dx.doi.org/10.2147/OPTH.S40798 |
work_keys_str_mv | AT kashimatomoyuki rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal AT itakurahirotaka rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal AT akiyamahideo rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal AT kishishoji rebamipideophthalmicsuspensionforthetreatmentofdryeyesyndromeacriticalappraisal |